

Oman Ministry of Health Updates



Ph. Sara Albalushi
Director of Pharmaceutical Care Department
Directorate General Of Medical Supplies

WHO 3rd Global Patient Safety Updates

- ☐ WHO update regarding Medication without harm
- □ Countries shared experiences and initiatives
- Oman
- Saudi Arabia
- United Kingdom
- United States
- Canada
- Australia
- Denmark
- Ireland



Aman system (Medication Error Reporting



Medication error Reporting system:

The Directorate General of Medical Supplies (DGMS) represented to Pharmaceutical Care department collaborated with Directorate General of Quality Assurance Center have integrated the medication error form electronically in the Incident Reporting & Learning System (IRLS), Aman.



Enhancing Medication Safety Officer's Role




Responsibilities of Medication Safety Committee

مهام لجان السلامة الدوائية بالمستشفيات

تتمثل المهمة الرئيسية للجنة السلامة الدوائية في قيادة وتنظيم كل The Drug Safety Committee's primary responsibility is to lead and regulate all aspects of the ما يتعلق باستراتيجيات وقواعد استخدام الأدوية بالمؤسسة بغرض promote the standards related to safe and effective drug use. These tasks can be detailed as follows:

- 1. Develop a comprehensive annual plan for all وضع خطة سنوية شاملة لمكونات برنامج السلامة الدوائية بالتعاون مع جميع الأقسام المعنية بالمؤسسة ، فيما يتعلق components of the drug safety program, in mechanisms, recording medication errors, يغرض الأخطاء والهسائل المقترحة للتنبؤ بحدوث الأخطاء والهسائل المقترحة للتنبؤ بحدوث الأخطاء بغرض تلافي الحدوث. وتعتمد هذه الخطة سنوناً بواسطة قبل العمل corrective actions to solve problems related to بها من قسم الرعابة الصيدلاتية بالمديرية العامة للتموين these errors, and the proposed means for predicting the occurrence of errors in order to avoid their occurrence. Prior to implementation, this plan is approved annually by the Pharmaceutical Care Department - the Directorate General of Medical Supplies
- واستخدام الأدوية بالمؤسسة الصحية بما في ذلك المواد , storage, transportation, and use of medicines including controlled substances, are followed in the health institution (psychotropic and narcotic
- 2) اعتماد ومراجعة السياسات والأجراءات المتعلقة بعملية إدارة Approving and reviewing drug management policies and procedures, collaborating with الأدوية والتعاون مع مسئولي أقسام المخازن الطبية والصيدلة

- organization's drug use strategies and rules to تعزيز المعايير المتعلقة بالاستخدام الآمن والفعال للأدوية. ويمكن تفصيل هذه المهام كما يلي:
- راليات استخدام الأدوية وتسجيل الأخطاء الدوائية collaboration with all concerned departments within the institution, regarding drug use والإجراءات التصحيحية لحل المشكلات المتعلقة بهذه
- 2. Ensure that approved safe practices for the ضمان اتباع الممارسات الآمنة المعتمدة لتخزين ونقل (1 الخاضعة للرقابة (الأدوية النفسية والمخدرة)



Medication Safety Officer Responsibilities

Medication Safety Officer Department As per organizational structure Bennits to: Pharmaceutical Care

General of Health Services Effective date:

مسؤول السلامة الدوانية المسمى الوظيفي:

الارتباط الوظيفي

تاريخ الإعناد:

ملخص المهام الوظيفية Scope of practice:

1. Participate in the provision of pharmaceutical المشاركة في تقديم الرعاية الصيدلية والسلامة الأدوية. care and current medication safety practices. المشاركة في توثيق الأخطاء التواتية. 2. Participatine in reporting medications error. عوثيق الأعراض الجاتبية للأدوية. 3. Reporting adverse drug reaction

In any health institution, the medication safety officer (MSO) is the person responsible for investigating reported or imminent medication errors due to الوقُّوع بسبب ممارسات خاطئة ، وتوفَّر المعلومات المتعلقة بعشية malpractices and providing information related to the الإستخدام الرشيد للدواء سواء للعاملين الصحيين أو المرضى تجنباً rational use of medication, whether for health workers or natients, in order to avoid any undesirable events in the future as a result of the use of these medications. The السلامة الدوائية يجب أن يكون على دراية كبيرة بكل ما يخس سلامة medication safety officer must be up to date on drug safety issues and be equipped with education and leadership skills to become the expert and approved الخبير والبرجعية المحمدة الموسسة الصحية في استخدام الألوية enference for the health institution concerning the safe

to tracking and inventorying the medication safety reports in the institution, identifying the pattern of these أولويك العل واصدار التوصيك اللازمة لفتع التكرار مسطيلاً involved, and the work environment so that he can identify work priorities, issue the necessary endations to prevent future recurrence, and follow up on the implementation of these recommendations cooperatively with the departments of

and competent medication safety officer, giving him the authority to act and make decisions in accordance with drug safety rules, and placing him in the organizational structure strengthens the ability to control the risks and errors associated with drug treatment

مسوول السلامة النوائية بالمؤسسة الصحية هو الشخص المنوط به التحقيق في الأخطاء النوانية المبلغ عن حنوثها أو وشيكة لأي أحداث خير مرخوبة مستقبلاً جراء استخدام هذه الأدوية. مسؤول الأدوية المستخدمة ومسلح بمهارات التطهم والقهادة لهصبح بمثابة بطريقة أمنة بغرجن الحدمن الضرر للمريحن.

ويوكل اليه أيضاً المهام الإحصائية المتطقة بتتبع وحصن He is also entrusted with statistical tasks related تقارير السلامة النوانية بالمؤسسة وتحديد نعط هذه الأخطاء وموقع حدوثها والأفراد المشتركين بها وبيئة العمل حتى يتمكن من تحديد ومتابعة تنفيذ هذه التوصيات بشكل تعاوني مع أقسام الصيدلة

وقد أثبتت العنيد من الدراسات أن قيام المسؤولين التفقيليون في مجال الرحاية الصحية بتوظيف مسئول سلامة نوائية موهل Many studies have shown that hiring a qualified ومختص ، ومنحه الصالاحيات للتصرف واتخاذ القرار وقفًا لقواحد السلامة الدوائية ، ووضعه على الهيكل التنظيمي للمؤسسة الصحية

Empowering Pharmacist Program

Patient Counselling







Anticoagulant Safety Program

thromboprophylaxis

for pregnancy and puerperium

Pharmacist Led Anticoagulant clinic



PHARMACEUTICAL CARE DEPARTMENT



Empowering pharmacist program

Low molecular weight Heparin counseling points









- Discuss and explain the importance of the anticoagulant Heparin Specify Indication, is it prophylaxis or treatment.
- If pregnant or breast feeding, assure patient about safety of use (safe to be used in pregnancy and breast feeding)

EXPECTED DURATION OF TREATMENT

Specify duration (Short or extended therapy), Reassure the patient and relatives of importance of following treatment or prophylaxis plan.

HOW TO TAKE LOW MOLECULAR WEIGHT HEPARIN

- LMW heparins are typically administered subcutaneously in fixed or weight-based dosing (and intravenously in acute myocardial infarction).
- Explain Timing and frequency
- Explain the strength
- Explain what patient can do if forgot the dose
- What to do if extra dose is taken accidentally What to do when abroad/crises/out stock
- Advice patient to inform pharmacist & health care professional if on low molecular weight Heparin & start new or Over the Counter (OTC) medication /herbal preparation/home remedy.
- Advice patient about Inter current illness (vomiting, diarrhea/ epileptic
- Advice patient and care giver about storage condition of LMWH, either in air conditioned room temperature below 25 Celsius depending on information specified by company, check the drug solution is clear and validity of expiry date.
- Hold the injection by barrel of syringe like pen, in the liquid of LMWH spot air bubble in the tip of syringe, it is essential to aid pushing all the medication out of the needle. Do not remove air bubble. Do not rub area of injection after injecting to avoid bruises.
- Ensure patient understand the appropriate area for injecting (around the navel or upper thigh and rotate between injections site, if bruised do not inject on bruised skin. Advice on proper injection technique under skin not into muscle.
- Inform patient about expecting slight pain during injecting and possibility of bruising at injection site.
- Dispose used injections in sharp containers or covered heavy materia plastic bottle and when full take it to nearest health institutions for appropriate disposal.

- Explain about bleeding risk that increase with low molecular weight heparin (LMWH) therapy as is the case with all anticoagulants.
- Oincrease in bleeding risk when combined with nonsteroidal anti inflammatory drug (NSAID) or aspirin, Anticoagulants, antiplatelets and thrombolytic, advice patient to avoid using OTC pain relievers like
- Inform patient of steps to be followed if suffered of any bleeding signs. advice on measures to reduce bleeding risk such as : use of soft tooth brush, taking care when using sharp instruments and knives, wear shoes or non slip socks or slippers in house to avoid injuries.

MONITORING

Educate patients about laboratory monitoring like (Hb or Hgb, Platelet,

CLOSING THE CONSULTATION

- Summarize the key point back to patient
- Ask patient to show you how to use injection
- Ask patient if they have any question or concern Arrange appropriate follow up





Ashifa System (Electronic Health System)



Electronic forms to Enhance Patient Safety

E	سلطنة عمان وزارة الصحة SULTANATE OF OMAN MINISTRY OF HEALTH	Hospital No: Name: Age: Nationality: Ward/Dept: Consultant: Unit									
	Isotretinoin Patient Consent Form										
	□Male	☐ Female									
	retinoin is prescribed to me for the trea icine the following information has bee	tment of acne. The doctor has explained all issues related to understood by me and I declare:	o this								
For F	Female patients:	56 56 5	6								
1	I should not take Isotretinoin if I'm pregnant or breast feeding or planning for pregnancy du to severe birth defect.										
2	I am not pregnant now (pregnancy test is done within last 11-days and is negative). I am not planning to become pregnant during Isotretinoin treatment & 1 month after therapy										
3	I must use two reliable methods of contraception, 1- month prior to therapy, during & 1- month after Isotretinoin (Isotretinoin will start 2nd or 3nd day of cycle).										
4	I should inform any doctor immediately & stop taking Isotretinoin if I become pregnant or believe I might be pregnant.										
For	Male & Female patient:		5 G								
5	I should not donate blood during treatment and 1- month after stopping therapy.										
6	I should call Dr. If experience any mood change or depression,										
7	I must avoid wax epilation & laser skin treatment during & 3-6 months after therapy.										
8	I should avoid sun light & use sun protection & lips balm.										
9	I should not take any Vitamin A Supplements.										
10	I should avoid driving, especially at night if I experience visual disturbance.										
11	I may feel decrease in tolerance with contact lenses during & after treatment.										
l c al N	Patient / Caregiver: confirm understanding all the above inform bout Isotretinoin therapy. lame: late:	Depression effect of Isotretinoin to patient caregiver. For female, therapy started base negative pregnancy test (If applicable). Dr: Name:	I state that I explained the Teratogenic & Depression effect of Isotretinoin to patient & or caregiver. For female, therapy started based on negative pregnancy test [if applicable]. Dr: Name: Date:								
			HP-25								

Clozapine Patient Monitoring Form

Hospital	Medical record number	PATIENT STICKER
NardUnit	NameAge	
reating doctor	Gender Nationality	
Consultant	Address	

Monitoring		Blood group: Date clozapine initiated:												
Paramedic	3	Results												
	required	1	Baseline Prior to clozapine		Date: Day 7//		Date: Day 14/		Date: Day 21//		Date: Day 28//		After 28 days	Remarks
	#	Date completed	Normal	Abnormal	Normal	Abnormal	Normal	Abnormal	Normal	Abnormal	Normal	Abnormal	1	=
1. Vital Signs*													Each Visit	
2. Physical Examination														
3. Height]	
4. Weight													1	
5. Waist													1	
6. BMI (weight (KG)/ Height (m2)														
7. Blood Tests*		•									•			
A. Complete Blood Count (CBC):													weekly for first 18 weeks then bio week for 18 week then	
Green results: WBCs 2 2,0x1				: WBCs between ≥ 3.0x10° & < 3.5x10° between ≥ 1.5x10° and < 2.0x10°			Red results: White blood cells < 3.0x10° & ANC < 1.5x10°				monthly after 1 year			
A.1 White Blood Cell (WBC)														
A.2 Absolute neutrophil count (ANC)														
A.3 Platelet Count													1	

Campaigns & Contributions

Campaigns


- Programs and awareness campaigns
- Patient safety day. Scientific program and public awareness campaign
- World Pharmacist day. Public awareness campaign

Contributions

- Patient safety friendly initiative in hospitals and primary health care policy and standards.
- National surveyors course
- Evaluation of Omani standards for health care system assessment.







THANK YOU